Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation (Q42984216)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 2009

Language	Label	Description	Also known as
English	Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation	scientific article published on January 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

peginterferon alfa-2a

1 reference

based on heuristic

inferred from title

author name string

Steffen Zopf

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Christoph Herold

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Eckhart G Hahn

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Marion Ganslmayer

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

486-490

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Antiviral therapy: chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802647400

21 January 2018

Identifiers

10.1080/00365520802647400

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42984216&oldid=1975854018"